Physician profile

Matthew Jensen

Oral and Maxillofacial Surgery · Peoria, AZ

NPI 1831438787

$517.31

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$94.86

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Straumann USA LLC $193.81 2019-2024
Scilex Pharmaceuticals INC. $151.63 2021-2022
Neurocrine Biosciences, INC. $57.26 2021
Nobel Biocare USA $27.86 2023 Nobelactive
Zimvie INC. $17.40 2024
Biohorizons Implant Systems INC. $16.72 2023 Biohorizons
Orapharma, A Division of Bausch Health US, LLC $16.27 2021
Ormco Corporation $13.93 2023 Spark
3m Company $11.30 2019
Dentsply Sirona INC $11.13 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Matthew Jensen

$517.31

in general payments reported 2019-2025

Years
2019-2024
Top company
Straumann USA LLC

https://glasscript.com/doctor/1346889/matthew-jensen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.